318 related articles for article (PubMed ID: 15266177)
41. Comparison of 18F-FDG and 68Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus.
Mäkinen TJ; Lankinen P; Pöyhönen T; Jalava J; Aro HT; Roivainen A
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1259-68. PubMed ID: 16007423
[TBL] [Abstract][Full Text] [Related]
42. Comparison of prone versus supine 18F-FDG-PET of locally advanced breast cancer: Phantom and preliminary clinical studies.
Williams JM; Rani SD; Li X; Arlinghaus LR; Lee TC; MacDonald LR; Partridge SC; Kang H; Whisenant JG; Abramson RG; Linden HM; Kinahan PE; Yankeelov TE
Med Phys; 2015 Jul; 42(7):3801-13. PubMed ID: 26133582
[TBL] [Abstract][Full Text] [Related]
43. Dual-phase 18F-FDG PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5.
Chen CJ; Lee BF; Yao WJ; Cheng L; Wu PS; Chu CL; Chiu NT
AJR Am J Roentgenol; 2008 Aug; 191(2):475-9. PubMed ID: 18647920
[TBL] [Abstract][Full Text] [Related]
44. Serial assessment of FDG-PET FDG uptake and functional volume during radiotherapy (RT) in patients with non-small cell lung cancer (NSCLC).
Edet-Sanson A; Dubray B; Doyeux K; Back A; Hapdey S; Modzelewski R; Bohn P; Gardin I; Vera P
Radiother Oncol; 2012 Feb; 102(2):251-7. PubMed ID: 21885145
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT oncologic imaging at extended injection-to-scan acquisition time intervals derived from a single-institution 18F-FDG-directed surgery experience: feasibility and quantification of 18F-FDG accumulation within 18F-FDG-avid lesions and background tissues.
Povoski SP; Murrey DA; Smith SM; Martin EW; Hall NC
BMC Cancer; 2014 Jun; 14():453. PubMed ID: 24942656
[TBL] [Abstract][Full Text] [Related]
46. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Costantini DL; Vali R; Chan J; McQuattie S; Charron M
AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
[TBL] [Abstract][Full Text] [Related]
47. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
48. Differentiation of malignant and benign cardiac tumors using 18F-FDG PET/CT.
Rahbar K; Seifarth H; Schäfers M; Stegger L; Hoffmeier A; Spieker T; Tiemann K; Maintz D; Scheld HH; Schober O; Weckesser M
J Nucl Med; 2012 Jun; 53(6):856-63. PubMed ID: 22577239
[TBL] [Abstract][Full Text] [Related]
49. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.
Christlieb SB; Strandholdt CN; Olsen BB; Mylam KJ; Larsen TS; Nielsen AL; Rohde M; Gerke O; Olsen KE; Møller MB; Kristensen BW; Abildgaard N; Alavi A; Høilund-Carlsen PF
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1824-36. PubMed ID: 27102266
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
[TBL] [Abstract][Full Text] [Related]
51. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
52. Prediction of prognosis using standardized uptake value of 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography for nasopharyngeal carcinomas.
Lee SW; Nam SY; Im KC; Kim JS; Choi EK; Ahn SD; Park SH; Kim SY; Lee BJ; Kim JH
Radiother Oncol; 2008 May; 87(2):211-6. PubMed ID: 18237806
[TBL] [Abstract][Full Text] [Related]
53. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
55. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
56. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
[TBL] [Abstract][Full Text] [Related]
57. 18F-FDG uptake and clearance in patients with compromised renal function.
Akers SR; Werner TJ; Rubello D; Alavi A; Cheng G
Nucl Med Commun; 2016 Aug; 37(8):825-32. PubMed ID: 27058366
[TBL] [Abstract][Full Text] [Related]
58. Chronic bacterial osteomyelitis: prospective comparison of (18)F-FDG imaging with a dual-head coincidence camera and (111)In-labelled autologous leucocyte scintigraphy.
Meller J; Köster G; Liersch T; Siefker U; Lehmann K; Meyer I; Schreiber K; Altenvoerde G; Becker W
Eur J Nucl Med Mol Imaging; 2002 Jan; 29(1):53-60. PubMed ID: 11807607
[TBL] [Abstract][Full Text] [Related]
59. Validation of fast-RAMLA in clinical PET.
Sato H; Cho K; Fukushima Y; Shiiba M; Hakozaki K; Kiriyama T; Sakurai M; Kanaya K; Kumita S
Ann Nucl Med; 2008 Dec; 22(10):869-76. PubMed ID: 19142705
[TBL] [Abstract][Full Text] [Related]
60. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
